This article, by Kenneth Yood and Christine Cohn of Sheppard Mullin, presents a summary of some of the key features in Senator Baucus’ health care bill that are particularly relevant to the drug industry and that merit close attention.
A recent program sponsored by the Seton Hall Law Center for Health and Pharmaceutical Law & Policy urged health care and life sciences companies to place a high degree of emphasis on developing and maintaining effective corporate compliance programs.
Scott Bruns and Kathleen Meriwether of Ernst & Young count down the top five compliance risks facing life sciences companies, including sales & marketing risks, the FCPA and IFRS, as well as supply-chain integrity and aggregate spend.
